Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Twynsta | Telmisartan/ Amlodipine | Hypertension | List | Complete | ||
Brilinta | Ticagrelor | Acute coronary syndromes | Do not list | Complete | ||
XGEVA | Denosumab | Prevention of skeletal-related events due to bone metastases from solid tumours | List with clinical criteria and/or conditions | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | ||
Gilenya | Fingolimod | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Victrelis | Boceprevir | Hepatitis C, chronic | List with clinical criteria and/or conditions | Complete | ||
Revolade | Eltrombopag olamine | Chronic immune thrombocytopenic purpura | Do not list | Complete | ||
Toctino | Alitretinoin | Eczema | List with clinical criteria and/or conditions | Complete | ||
Victoza | Liraglutide | Diabetes mellitus, Type 2 | Do not list | Complete |